Extended Data Fig. 10. Characterization of R1-32 like mAbs.

a, Competition between R1-32 like mAbs and R1-32 for binding to SARS-CoV-2 RBD. b, Competition between R1-32 like mAbs and ACE2-Fc for binding to SARS-CoV-2 RBD. Competition assays were performed by BLI. SARS-CoV-2 RBD was immobilized onto Anti-His biosensors, immobilized RBD was saturated with R1-32 or ACE2-Fc, followed by incubation with R1-32 like mAbs (colored lines). As controls, biosensors immobilized with RBD was first equilibrated in buffer before submerging into ACE2-Fc or R1-32 solutions (black traces). c, Binding of R1-32 like mAbs to RBD point mutants or VOC RBDs. R1-32 and R1-32 like mAbs (C963, C978, C941, C091, C092, C807, and C832) were immobilized onto Protein A biosensors and submerged into RBD solutions (at 200 nM) to record sensorgram traces. Kinetic parameters are summarized in Supplementary Table 9.